v3.26.1
Segment Information (Details Narrative)
$ in Thousands
12 Months Ended
Dec. 31, 2025
USD ($)
Segment
Dec. 31, 2024
USD ($)
Segment Reporting Information [Line Items]    
Number of operating segments | Segment 2  
Number of reporting segments | Segment 2  
Operating expenses $ 27,556 $ 24,677
Segment net loss 26,609 23,486
Total assets 39,393 41,561
Biopharm Division [Member]    
Segment Reporting Information [Line Items]    
Operating expenses 24,900  
Segment net loss 24,103 21,254
Total assets 38,900  
Neurostimulation Division [Member]    
Segment Reporting Information [Line Items]    
Operating expenses 2,600  
Segment net loss 2,506 $ 2,232
Total assets $ 500